Studies related to Visual Acuity and CDP-choline

Evidence Of The Neuroprotective Role Of Citicoline In Glaucoma Patients

Effect Increase
Trial Design Cohort
Trial Length 1-6 months
Number of Subjects 60
Gender Both Genders
Age Range 30-44, 45-64
Body Types Overweight, Average
Notes for this study:
1600mg oral CDP-choline to persons with glaucoma and minor visual impairment for 60 days (with 180 days of followup) noted that CDP-choline was associated with improvements in visual functoning without any influence on intraocular pressure. Although a control was used in this study, there was no blinding protocol.